Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients

Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients

Mutations in the SARS-CoV-2 Spike glycoprotein can affect monoclonal antibody efficacy. Recent findings report the occurrence of resistant mutations in immunocompromised patients after tixagevimab/cilgavimab treatment. More recently, the Food and Drug Agency revoked the authorization for tixagevimab...

Full description

Bibliographic Details
Main Authors: Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Martina Rueca, Valentina Mazzotta, Giulia Gramigna, Alessandra Vergori, Lavinia Fabeni, Giulia Berno, Emanuela Giombini, Ornella Butera, Daniele Focosi, Ingrid Guarnetti Prandi, Giovanni Chillemi, Emanuele Nicastri, Francesco Vaia, Enrico Girardi, Andrea Antinori, Fabrizio Maggi
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Biomolecules
Subjects:
tixagevimab
cilgavimab
Spike
mAbs
SARS-CoV-2
mutations
Online Access:https://www.mdpi.com/2218-273X/13/10/1538

Internet

https://www.mdpi.com/2218-273X/13/10/1538

Similar Items